NCT07354126 Comparative Efficacy of Flunarizine and Propanolol in Pediatric Migraine
| NCT ID | NCT07354126 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Muhammad Aamir Latif |
| Condition | Migraine |
| Study Type | INTERVENTIONAL |
| Enrollment | 44 participants |
| Start Date | 2025-09-01 |
| Primary Completion | 2026-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 44 participants in total. It began in 2025-09-01 with a primary completion date of 2026-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Flunarizine and propranolol have demonstrated efficacy in reducing migraine frequency across age groups, though evidence in pediatric populations remains limited and inconsistent. Therefore, the current study has been planned to evaluate and compare the effectiveness of flunarizine and propranolol in reducing migraine frequency in children aged 8-15 using the Pediatric Migraine Disability Assessment Scale (PedMIDAS) score.
Eligibility Criteria
Inclusion Criteria: * Children of any gender * Aged 8-15 years * Diagnosed with migraine (with/without aura) per International Classification of Headache Disorders, 3rd Edition (ICHD-3) criteria * A history of ≥4 migraine attacks/month for the preceding 3 months * With a PedMIDAS score ≥11 (moderate-to-severe impact) Exclusion Criteria: * Children with secondary headache disorders (e.g., due to infections, trauma, structural brain lesions) * Known hypersensitivity or contraindications to flunarizine or propranolol * Presence of cardiovascular disorders (e.g., bradycardia, heart block, hypotension, asthma) * Non-compliance or inability to attend regular follow-ups * Participation in another clinical trial within the last 3 months
Contact & Investigator
Ishafaq Ahmed, FCPS
PRINCIPAL INVESTIGATOR
The Children's Hospital Lahore
Frequently Asked Questions
Who can join the NCT07354126 clinical trial?
This trial is open to participants of all sexes, aged 8 Years or older, up to 15 Years, studying Migraine. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07354126 currently recruiting?
Yes, NCT07354126 is actively recruiting participants. Contact the research team at quaidian245ishfaq@gmail.com for enrollment information.
Where is the NCT07354126 trial being conducted?
This trial is being conducted at Lahore, Pakistan.
Who is sponsoring the NCT07354126 clinical trial?
NCT07354126 is sponsored by Muhammad Aamir Latif. The principal investigator is Ishafaq Ahmed, FCPS at The Children's Hospital Lahore. The trial plans to enroll 44 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.